



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Epalrestat (Standard)

Cat. No.:	HY-66009R
CAS No.:	82159-09-9
Molecular Formula:	C ₁₅ H ₁₃ NO ₃ S ₂
Molecular Weight:	319.4
Target:	Aldose Reductase
Pathway:	Metabolic Enzyme/Protease
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description

Epalrestat (Standard) is the analytical standard of Epalrestat. This product is intended for research and analytical applications. Epalrestat is an orally active aldose reductase inhibitor that acts on diabetic neuropathy^{[1][2][3]}.

REFERENCES

- [1]. Ramirez, M.A. and N.L. Borja, Epalrestat: an aldose reductase inhibitor for the treatment of diabetic neuropathy. *Pharmacotherapy*, 2008. 28(5): p. 646-55.
- [2]. Okamoto, H., et al., Effects of epalrestat, an aldose reductase inhibitor, on diabetic neuropathy and gastroparesis. *Intern Med*, 2003. 42(8): p. 655-64.
- [3]. Hotta, N., et al., Clinical investigation of epalrestat, an aldose reductase inhibitor, on diabetic neuropathy in Japan: multicenter study. Diabetic Neuropathy Study Group in Japan. *J Diabetes Complications*, 1996. 10(3): p. 168-72.
- [4]. He J, et al. The aldose reductase inhibitor epalrestat exerts nephritic protection on diabetic nephropathy in db/db mice through metabolic modulation. *Acta Pharmacol Sin*. 2019 Jan;40(1):86-97.
- [5]. Sato K, et al. Epalrestat increases intracellular glutathione levels in Schwann cells through transcription regulation. *Redox Biol*. 2013 Nov 19;2:15-21.
- [6]. Li QR, et al. Epalrestat protects against diabetic peripheral neuropathy by alleviating oxidative stress and inhibiting polyol pathway. *Neural Regen Res*. 2016 Feb;11(2):345-51.
- [7]. Zhang T, et al. The Aldose Reductase Inhibitor Epalrestat Maintains Blood-Brain Barrier Integrity by Enhancing Endothelial Cell Function during Cerebral Ischemia. *Mol Neurobiol*. 2023 Jul;60(7):3741-3757.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA